ABNX ABIONYX Pharma SA

EPA · FR · Healthcare · Biotechnology · abionyx.com

1.622EUR-5.04%Mkt Cap: 76.71M $P/E: —3d ago

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap76.71M USD

Enterprise Value65.83M USD

Revenue (TTM)4.42M USD

Gross Profit580.43K USD

Net Income (TTM)-6.03M USD

Revenue/Share0.12 EUR

Last Price1.622 EUR

Fiscal Year EndDec 2025

MR QuarterDec 2025

Employees49

CountryFR

SectorHealthcare

IndustryBiotechnology

ISINFR0012616852

Valuation

P/E (Trailing)—

P/E (Forward)-5.16

PEG—

EV/EBITDA-11.17

EV/Revenue14.91

P/S18.29

P/B13.34

EPS (TTM)-0.22

EPS (Forward)-0.33

52W Range

1.6140% of range5.290

52W High5.290 EUR

52W Low1.614 EUR

Profitability

Gross Margin13.14%

Oper. Margin-165.02%

EBITDA Margin-133.47%

Profit Margin-136.60%

ROE-123.01%

ROA-42.32%

Growth

Revenue Growth-11.90%

Earnings Growth—

Cash Flow & Leverage

Operating CF-3.19M USD

CapEx (TTM)263.04K USD

FCF Margin-7.07%

FCF Yield-0.41%

Net Debt308.70K USD

Net Debt/EBITDA-0.05

Balance Sheet

Debt/Equity0.84

Current Ratio1.06

Quick Ratio0.99

Book Value/Sh0.13 EUR

Cash/Share0.10 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)9.833 EUR

Upside (mean)+506.2%

Target Range8.500 EUR – 11.00 EUR

8.500+506.2% to mean11.00

# Analysts3

Ownership

Shares Out.43.51M

Float22.34M

Insiders29.17%

Institutions3.64%

Technical

SMA 501.897 (-14.5%)

SMA 2002.886 (-43.8%)

Beta0.46

S&P 52W Chg13.94%

Avg Vol (30d)163.52K

Avg Vol (10d)142.99K

Technical Indicators

RSI (14)34.0

MACD-0.0546

MACD Signal-0.0427

MACD Hist.-0.0119

BB Upper1.961 EUR

BB Middle1.793 EUR

BB Lower1.626 EUR

BB Width18.66%

ATR (14)0.0869 EUR

Vol Ratio (20d)1.46x